Scilex (SCLX) Stock Price, News & Analysis

Company Overview

Scilex Holdings, Inc. (NASDAQ: SCLX) is a specialty pharmaceutical company focused on non-opioid treatments for chronic pain. The firm’s principal commercial product, ZTlido®, is a lidocaine topical system approved by the U.S. Food and Drug Administration for the management of post-herpetic neuralgia and certain peripheral neuropathic pain conditions. By leveraging a proprietary drug delivery platform, Scilex aims to improve patient comfort and safety compared to traditional oral analgesics.

In addition to marketing ZTlido® in the United States, Scilex is advancing other pain management assets through clinical development and regulatory pathways. The company’s pipeline includes additional topical and localized therapies designed to address a range of acute and chronic pain indications without the abuse potential associated with opioid medications. Scilex pursues both in-house research and selective licensing partnerships to broaden its offering.

Headquartered in San Diego, California, Scilex operates primarily in the U.S. market, where it works with healthcare providers, specialty pharmacies and distributors to ensure patient access to its products. The company’s management team brings experience in pharmaceutical development, regulatory affairs and commercial operations, supporting Scilex’s strategy of targeted growth within the pain therapeutics space.

Key Stats

• Today's Range: $25.00 to $27.09
• 50-Day Range: $6.25 to $26.28
• 52-Week Range: $3.60 to $41.30
• Volume: 342,895 shs
• Average Volume: 213,275 shs
• Market Capitalization: $182.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $455.00
• Consensus Rating: Moderate Buy

Scilex Stock Analysis - MarketRank™

Scilex scored higher than 44% of companies evaluated by MarketBeat, and ranked 709th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Scilex has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Scilex has a consensus price target of $455.00, representing about 1,631.4% upside from its current price of $26.28.

Amount of Analyst Coverage

Scilex has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Scilex are expected to grow in the coming year, from ($0.57) to ($0.41) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Scilex is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Scilex is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.76% of the float of Scilex has been sold short.

Short Interest Ratio / Days to Cover

Scilex has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Scilex has recently increased by 10.72%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Scilex does not currently pay a dividend.

Dividend Growth

Scilex does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.76% of the float of Scilex has been sold short.

Short Interest Ratio / Days to Cover

Scilex has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Scilex has recently increased by 10.72%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 1.78

News Sentiment

Scilex has a news sentiment score of 1.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Scilex this week, compared to 2 articles on an average week.

Search Interest

25 people have searched for SCLX on MarketBeat in the last 30 days. This is an increase of 19% compared to the previous 30 days.

MarketBeat Follows

Only 5 people have added Scilex to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Scilex insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.94% of the stock of Scilex is held by insiders.

Percentage Held by Institutions

69.67% of the stock of Scilex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SCLX Stock Analysis - Frequently Asked Questions

How have SCLX shares performed this year?

Scilex's stock was trading at $14.9240 on January 1st, 2025. Since then, SCLX stock has increased by 76.1% and is now trading at $26.28.

How were Scilex's earnings last quarter?

Scilex Holding Company (NASDAQ:SCLX) posted its quarterly earnings data on Wednesday, August, 13th. The company reported ($7.42) EPS for the quarter, missing the consensus estimate of ($4.55) by $2.87. The business had revenue of $9.90 million for the quarter, compared to the consensus estimate of $26.25 million.

When did Scilex's stock split?

Shares of Scilex reverse split on Tuesday, April 15th 2025.The 1-35 reverse split was announced on Friday, April 11th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 14th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are Scilex's major shareholders?

Top institutional shareholders of Scilex include Geode Capital Management LLC (0.89%), Rafferty Asset Management LLC (0.25%), Norges Bank (0.20%) and Bank of America Corp DE (0.14%). Insiders that own company stock include Henry Ji, Jaisim Shah, Jay Chun, Yue Alexander Wu and Stephen Hoi Ma.
View institutional ownership trends.

How do I buy shares of Scilex?

Shares of SCLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Scilex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Scilex investors own include Rigetti Computing (RGTI), Pfizer (PFE), BioNTech (BNTX), Hertz Global (HTZ), BlackBerry (BB).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 9/13/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SCLX
• CIK: 1820190
• Web: www.scilexholding.com
• Phone: 650-516-4310
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Scilex: $455.00
• High Price Target: $630.00
• Low Price Target: $245.00
• Potential Upside/Downside: +1,631.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($29.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$72.81 million
• Net Margins: -179.12%
• Pretax Margin: -183.01%
• Return on Equity: N/A
• Return on Assets: -109.95%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.11
• Quick Ratio: 0.10

Sales & Book Value

• Annual Sales: $56.59 million
• Price / Sales: 3.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($27.68) per share
• Price / Book: -0.95

Miscellaneous

• Outstanding Shares: 6,960,000
• Free Float: 6,404,000
• Market Cap: $182.91 million
• Optionable: Optionable
• Beta: 1.34